New Century Pharmaceuticals, Inc.
A Biotechnology Research & Development Company
- Pioneering Tomorrow's Therapeutics -
About
Notable R&D:
- Completion of a major structural survey of drug transport chemistry at atomic resolution for the purposes of designing improvements in the safety and efficacy of pharmaceuticals
- Pioneering the development of self-assembling nanoparticles for diagnostic, therapeutic and vaccine applications. NCP self-assembling ferritin nanoparticles are currently transforming the approach to vaccine development
Technologies & Services
Microgravity Science & Applications
NCP has been an early pioneer in material science applications in microgravity with science and hardware development support services related to macromolecular crystal growth. Historically, our company and experience has included a highly successful series of multi-user payloads flown under contract though NASA on the Space Shuttle, the Russian Mir Space Station, and the International Space Station.
Learn More
Self Assembling Nanoparticle Therapeutic & Vaccine Applications
NCP's self-assembling ferritin nano particles are currently transforming the development of new vaccines.
Learn MoreContact
- 895 Martin Road Southwest, Huntsville, AL, United States
- 895 Martin Road, SW, STE C 35824
Management
Daniel C. Carter, Ph.D.
President
Dr. Carter has served as the President and CEO of New Century Pharmaceuticals since 1997. With a passion for science in the public interest, Dr. Carter maintains an active role in research with extensive experience in molecular structural biology, protein engineering, protein production and related microgravity applications.
News
- (2017) Teledyne-Brown Engineering and New Century Pharmaceuticals were awarded a 5 year contract from the Center for the Advancement of Science in Space (CASIS) to provide science services and support for biotechnology based experiments on the International Space Station. The contract will focus on science support and flight hardware integration of multi-user protein crystal growth experiments using flight approved hardware designed or developed by NCP scientists
Articles
As the principal protein of the circulatory system, albumin is a major effector of drug pharmacokinetics. Albumin sequestration of drugs often renders them less effective requiring higher dosing with increased cytotoxicity.
Read More
As the principal protein of the circulatory system, albumin is a major pharmacokinetic effector of pharmaceuticals, playing an important role in therapeutic bioavailability and half-life.
Read More
